Risperidone vs. Paroxetine for Panic Attacks
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00206765 |
Recruitment Status
:
Terminated
First Posted
: September 21, 2005
Last Update Posted
: October 22, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Major Depressive Disorder With Panic Attacks Panic Disorder | Drug: Risperidone Drug: Paroxetine | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks |
Study Start Date : | January 2003 |
Actual Primary Completion Date : | July 2005 |
Actual Study Completion Date : | July 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females, ages 21-55.
- Ability to sign an informed consent
- Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
- HAM-A score >17
Exclusion Criteria:
- Alcohol or substance abuse within the last 6 months
- Current diagnosis of Obsessive-Compulsive Disorder
- Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
- Use of antipsychotic medications over the two months preceding enrollment in the study
- Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
- Previous adverse reaction to risperidone or paroxetine.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00206765
United States, New York | |
Beth Israel Medical Center | |
New York, New York, United States, 10003 |
Principal Investigator: | Igor Galynker, MD, PhD | Beth Israel Medical Center |
Responsible Party: | Beth Israel Medical Center |
ClinicalTrials.gov Identifier: | NCT00206765 History of Changes |
Other Study ID Numbers: |
082-02 |
First Posted: | September 21, 2005 Key Record Dates |
Last Update Posted: | October 22, 2012 |
Last Verified: | October 2012 |
Keywords provided by Beth Israel Medical Center:
panic |
Additional relevant MeSH terms:
Disease Depressive Disorder Depression Depressive Disorder, Major Panic Disorder Pathologic Processes Mood Disorders Mental Disorders Behavioral Symptoms Anxiety Disorders Risperidone Paroxetine Serotonin Antagonists Serotonin Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Antidepressive Agents, Second-Generation Antidepressive Agents Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors |